Clusterin has been shown to be implicated in the acquisition of resistant phenotype to various kinds of apoptotic stimuli, including radiation. In
bladder cancer, our previous study demonstrated that overexpression of
clusterin is closely associated with
disease progression and recurrence. The objective of this study was to investigate whether radiation sensitivity was enhanced by suppressing
clusterin gene expression with antisense (AS)
oligodeoxynucleotide (ODN) in the human
bladder cancer KoTCC-1 model.
Clusterin mRNA in KoTCC-1 cells after radiation was up-regulated in a dose-dependent manner; however, AS
clusterin ODN treatment resulted in a marked inhibition of
clusterin mRNA even after irradiation. Combined treatment of KoTCC-1 cells with radiation and AS
clusterin ODN synergistically decreased plating efficacy and induced apoptotic cell death compared with either radiation or AS
clusterin ODN treatment alone. In vivo systemic administration of AS
clusterin ODN enhanced radiation sensitivity, significantly reducing subcutaneous KoTCC-1
tumor volume in nude mice, compared with that of mismatch control ODN. Moreover, additional administration of
cisplatin to this combined regimen further achieved potential antitumor effects on subcutaneous KoTCC-1
tumor growth in nude mice. Collectively, these findings suggest that
clusterin acts as a cell survival
protein mediating radioresistance through the inhibition of apoptosis, and that inactivation of
clusterin using AS technology might offer a novel strategy to improve the outcome of
radiation therapy for patients with
bladder cancer.